Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

krema - hidrokortizon

Evropska unija - slovenščina - EMA (European Medicines Agency)

pharmaand gmbh - darifenacin hidrobromid - urinary incontinence, urge; urinary bladder, overactive - urologicals, droge za sečil, pogostost in inkontinenco - simptomatsko zdravljenje urgentne inkontinence in / ali povečane frekvence in urina urina, ki se lahko pojavi pri odraslih bolnikih s sindromom čezmernega aktivnega mehurja.

Evropska unija - slovenščina - EMA (European Medicines Agency)

pharmaand gmbh - brezvodni panobinostat laktat - multiple myeloma - antineoplastična sredstva - farydak, v kombinaciji z bortezomiba in deksametazon, je indicirano za zdravljenje odraslih bolnikov s ponovila in/ali ognjevarnih multipli mielom, ki so prejeli vsaj dve predhodno režimi, vključno z bortezomiba in imunomodulatorne agent. farydak, v kombinaciji z bortezomiba in deksametazon, je indicirano za zdravljenje odraslih bolnikov s ponovila in/ali ognjevarnih multipli mielom, ki so prejeli vsaj dve predhodno režimi, vključno z bortezomiba in imunomodulatorne agent.

Evropska unija - slovenščina - EMA (European Medicines Agency)

pharmaand gmbh - peginterferon alfa-2a - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b adult patients pegasys is indicated for the treatment of hepatitis b envelope antigen (hbeag)-positive or hbeag-negative chronic hepatitis b (chb) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (alt) and histologically verified liver inflammation and/or fibrosis (see sections 4. 4 in 5. paediatric patients 3 years of age and older pegasys is indicated for the treatment of hbeag-positive chb in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum alt levels. glede na odločitev, da začne zdravljenje v pediatrični bolniki glej točki 4. 2, 4. 4 in 5. chronic hepatitis c adult patients pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease (see sections 4. 2, 4. 4 in 5. za virus hepatitisa c (hcv) genotip določene dejavnosti, glej točki 4. 2 in 5. paediatric patients 5 years of age and older pegasys in combination with ribavirin is indicated for the treatment of chc in treatment-naïve children and adolescents 5 years of age and older who are positive for serum hcv-rna. ko se odločate za začetek zdravljenja v otroštvu, je pomembno, da preuči zaviranja rasti povzročijo kombinacija terapije. reverzibilnost zaviranja rasti je negotova. odločitev za zdravljenje mora biti vložena na podlagi primera (glej poglavje 4.

Evropska unija - slovenščina - EMA (European Medicines Agency)

pharmaand gmbh - rucaparib camsylate - ovarijske neoplazme - antineoplastična sredstva - rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. rubraca je označen kot monotherapy za vzdrževanje zdravljenje odraslih bolnikov s platino-občutljive relapsed visoko-kakovostni razred epitelnih jajčnikov, fallopian tube, ali primarni trebušno raka, ki so v odziv (popolna ali delna) platinum, ki temelji kemoterapijo.

Evropska unija - slovenščina - EMA (European Medicines Agency)

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - druga zdravila na živčnem sistemu - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

teva b.v. - ivabradin - filmsko obložena tableta - ivabradin 7,5 mg / 1 tableta - ivabradin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

teva b.v. - ivabradin - filmsko obložena tableta - ivabradin 5 mg / 1 tableta - ivabradin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

teva b.v. - ivabradin - filmsko obložena tableta - ivabradin 5 mg / 1 tableta - ivabradin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

teva b.v. - ivabradin - filmsko obložena tableta - ivabradin 7,5 mg / 1 tableta - ivabradin